Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer
JAMA Network Open · 12.03.2026 · 9 (3) · e261543
DOI: 10.1001/jamanetworkopen.2026.1543 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 12.03.2026. Verfasst von Xiaoyu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles. Hauptthemen laut MEDLINE: Smoking Cessation, Cost-Benefit Analysis, Uterine Cervical Neoplasms, Uterine Cervical Dysplasia. Die Arbeit nennt 37 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Evidence of cost-effectiveness is needed to demonstrate the value of smoking cessation behavioral interventions.
Objective
To evaluate the cost-effectiveness of motivation and problem-solving (MAPS) against standard treatment (ST) for smoking cessation among patients with a history of cervical intraepithelial neoplasia or cervical cancer. Design, Setting, and Participants In this economic evaluation, a cost-effectiveness analysis was conducted from the perspective of cancer centers using data collected in a randomized clinical trial conducted between February 2017 and January 2020 with follow-up until August 2021 that compared MAPS with ST. MAPS is a behavioral intervention that emphasizes smoking cessation and relapse prevention while addressing life events, stressors, and other individual concerns. The trial included up to 6 counseling sessions of MAPS delivered over 12 months. Data were analyzed from January 2024 to December 2025. Exposure Inclusion in a smoking cessation randomized clinical trial that compared MAPS with ST. Main Outcomes and Measures Deterministic and probabilistic cost-effectiveness analyses were conducted and findings were reported as incremental cost-effectiveness ratio and cost-effectiveness acceptability curve, respectively, for 7-day point prevalence abstinence at months 12 and 18.
Results
The analysis included 194 participants. Study participants had a mean (SD) age of 47.8 (10.8) years, had a mean (SD) smoking history of 29.1 (12.1) years, and smoked a mean (SD) of 15.5 (8.7) cigarettes per day. Mean costs were $522.74 (95% CI, $500.19 to $545.29) and $389.26 (95% CI, $362.67 to $415.84) per participant for MAPS (98 participants) and ST (96 participants), respectively. At month 12, abstinence rates were 26.5% and 12.5% for MAPS and ST, respectively. The deterministic analysis found that the incremental cost for MAPS vs ST was $921 per quit at month 12 and $7458 per quit at month 18. The probabilistic analysis found that at the societal willingness to pay of $10 000 per quit, the probability that MAPS is cost-effective at month 12 was nearly 100% but reduced to 52% at month 18. Subgroup analysis found a lower incremental cost-effectiveness ratio when comparing the high MAPS engagement subgroup with the ST group. The cost-effectiveness of MAPS (vs ST) was sustained at month 18 among the high MAPS engagement subgroup despite a decline in 7-day abstinence. Conclusions and Relevance In this cost-effectiveness analysis, there was robust evidence supporting the cost-effectiveness of MAPS (vs ST) at month 12 and moderate evidence at month 18 in terms of incremental cost per quit. The attenuation of intervention outcome over time was more pronounced among participants with less than 4 sessions of MAPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles.
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
- Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa.
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
- Department of Psychology, University of South Florida, Tampa.
- University of Utah and Huntsman Cancer Institute, Salt Lake City.
Förderung
- NCI NIH HHS
Zitieren
APA
Liu, X., Vidrine, D. J., Sutton, S. K., Wetter, D. W., Jones, S. R., Vidrine, J. I., & Shih, Y. T. (2026). Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. JAMA Network Open, 9(3), e261543. https://doi.org/10.1001/jamanetworkopen.2026.1543
Vancouver
Liu X, Vidrine DJ, Sutton SK, Wetter DW, Jones SR, Vidrine JI, et al. Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. JAMA Network Open. 2026;9(3):e261543. doi:10.1001/jamanetworkopen.2026.1543
BibTeX
@article{Liu2026,
author = {Liu, Xiaoyu and Vidrine, Damon J and Sutton, Steven K and Wetter, David W and Jones, Sarah R and Vidrine, Jennifer I and Shih, Ya-Chen Tina},
title = {Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {3},
pages = {e261543},
doi = {10.1001/jamanetworkopen.2026.1543}
}
EUVIMED